FDA Sets Date For Resubmitted Dupixent in Inflammatory Skin Disease
The FDA has accepted the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric...
date
FDA Sets Review Date for Tagrisso for Specific Lung Cancer Mutations
The FDA has granted priority review for AstraZeneca’s supplemental new drug application for Tagrisso (osimertinib) to treat adult patients with...
